PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25739982-6	2015	U0126 (5 muM), a specific inhibitor of (MEK1/2), and 10-DEBC (2 muM), a selective inhibitor of AKT, both significantly reduced 17beta-estradiol-induced phosphorylation of mTOR.	U 0126	0-5	mechanistic target of rapamycin kinase	Homo sapiens	171-175	
24012499-9	2013	This effect was attenuated by treatment with the pharmacological inhibitors U0126, LY294002 and rapamycin, which selectively block the activation of ERK1/2, Akt and mTOR, respectively, and siRNAs directed against ERK1/2, Akt and mTOR.	U 0126	76-81	mechanistic target of rapamycin kinase	Homo sapiens	165-169	
24036423-4	2014	Investigation of the role of p44/42 and mTOR on metabolic activity and protein content per cell, demonstrated that in the presence of MAPK inhibitor U0126 and mTOR inhibitor Ku-63794, that the mTOR pathway is responsible for the reduction in PTC metabolic activity in response to leptin.	U 0126	149-154	mechanistic target of rapamycin kinase	Homo sapiens	40-44	
24451985-9	2014	Furthermore, VEGF significantly stimulated proliferation and migration of pTr cells, but these effects were blocked by SB203580, U0126, rapamycin, and LY294002, which inhibit p38 MAPK, ERK1/2, mTOR, and PI3K, respectively.	U 0126	129-134	mechanistic target of rapamycin kinase	Homo sapiens	193-197	
24012499-9	2013	This effect was attenuated by treatment with the pharmacological inhibitors U0126, LY294002 and rapamycin, which selectively block the activation of ERK1/2, Akt and mTOR, respectively, and siRNAs directed against ERK1/2, Akt and mTOR.	U 0126	76-81	mechanistic target of rapamycin kinase	Homo sapiens	229-233	
23904987-10	2013	U0126 leads to the reduction of MAPK and mTOR pathways activation in all cell lines tested.	U 0126	0-5	mechanistic target of rapamycin kinase	Homo sapiens	41-45	
21854819-5	2011	The insulin-induced increase of tau protein level was abolished by LY294002 [an inhibitor of phosphoinositide 3-kinase (PI3K)] and rapamycin [an inhibitor of mammalian target of rapamycin (mTOR)], but not by PD98059 and U0126 [two inhibitors of mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK)].	U 0126	220-225	mechanistic target of rapamycin kinase	Homo sapiens	158-187	
23453973-6	2013	We then treated glucose-replete and -depleted cells with SB415286, U0126, LY294 and rapamycin to inhibit GSK3, MEK1/2, PI3K and mTOR, respectively.	U 0126	67-72	mechanistic target of rapamycin kinase	Homo sapiens	128-132	
22401294-11	2012	Finally, we also observed that the efficacy of ATP-competitive inhibitors of mTOR was enhanced by U0126, a MEK inhibitor.	U 0126	98-103	mechanistic target of rapamycin kinase	Homo sapiens	77-81	
22101421-0	2012	The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK             inhibitor U0126 in non-small cell lung cancer cells.	U 0126	90-95	mechanistic target of rapamycin kinase	Homo sapiens	20-24	
22156391-9	2011	Also, NAC, LY294002, U0126, GSK733, which all indirectly inhibit mTOR and have been shown to suppress the senescent phenotype in traditional models of mammalian cell senescence, also decreased lactate production and decelerated CS.	U 0126	21-26	mechanistic target of rapamycin kinase	Homo sapiens	65-69	
11940578-6	2002	Dominant negative c-Raf expression or a MEK1/2 inhibitor (U0126) treatment showed a profound blocking effect only on the TPA-stimulated phosphorylation of S6K1 and mTOR.	U 0126	58-63	mechanistic target of rapamycin kinase	Homo sapiens	164-168	
18981735-7	2008	The combination of rapamycin with the MEK inhibitor U0126 significantly enhanced growth inhibitory effects of cancer cells, suggesting that MEK/ERK activation may counteract mTOR inhibitors" anticancer efficacy.	U 0126	52-57	mechanistic target of rapamycin kinase	Homo sapiens	174-178	
12489846-2	2002	We reported that the mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts by simultaneously blocking both extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin (mTOR)-p70(S6K) pathways.	U 0126	108-113	mechanistic target of rapamycin kinase	Homo sapiens	271-300	
12489846-2	2002	We reported that the mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts by simultaneously blocking both extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin (mTOR)-p70(S6K) pathways.	U 0126	108-113	mechanistic target of rapamycin kinase	Homo sapiens	302-306	
31586300-3	2020	The object of this study is recognition of the possible role of mTOR kinase inhibitors-everolimus single and in combination with selected downstream protein kinases inhibitors: LY294002 (PI3 K), U0126 (ERK1/2), GDC-0879 (B-RAF), AS-703026 (MEK), MK-2206 (AKT), PLX-4032 (B-RRAF) in cell invasion in malignant melanoma.	U 0126	195-200	mechanistic target of rapamycin kinase	Homo sapiens	64-68	
30621146-8	2019	Using the inhibitors of MAPK/ERK, U0126, we found that the crosstalk among the signaling pathways of MAPK/ERK, Akt-mTOR, and the inflammatory adipogenesis can be the possible mechanism of salt-linked obesity.	U 0126	34-39	mechanistic target of rapamycin kinase	Homo sapiens	115-119	
29554648-11	2018	Moreover, the Erk inhibitor U0126 prevented HG-induced mTOR activation.	U 0126	28-33	mechanistic target of rapamycin kinase	Homo sapiens	55-59	
28943602-9	2017	DM-induced neurite outgrowth was abolished by U0126 and rapamycin, indicating the involvement of the mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) pathways.	U 0126	46-51	mechanistic target of rapamycin kinase	Homo sapiens	145-174	
28943602-9	2017	DM-induced neurite outgrowth was abolished by U0126 and rapamycin, indicating the involvement of the mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) pathways.	U 0126	46-51	mechanistic target of rapamycin kinase	Homo sapiens	176-180	
28734155-8	2017	Moreover, the anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex-induced phosphorylation of mTOR in THP-1 cells was down-regulated through inhibition of p38 (10muM, SB203580) or ERK (5muM, U0126) rather than inhibition of JNK (90nM, SP600125) or NF-kappaB (20muM, PDTC).	U 0126	189-194	mechanistic target of rapamycin kinase	Homo sapiens	92-96	
33412209-6	2021	However, U0126, a potent extracellular signal-regulated kinase 1/2 (Erk1/2) inhibitor, decreased PDGF-BB-induced LC3 expression, while rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), increased it.	U 0126	9-14	mechanistic target of rapamycin kinase	Homo sapiens	197-201	
30271499-4	2018	MEK inhibitor U0126 can lead to dephosphorylation of MTOR and Rictor in COLO-16 cells; however, c-Raf was not yet down-regulated after salirasib treatment in the presence of U0126.	U 0126	14-19	mechanistic target of rapamycin kinase	Homo sapiens	53-57	
28990465-6	2017	Moreover, combined treatment of U0126, a mitogen-activated protein kinase kinase 1/2 inhibitor, and rapamycin, a mammalian target of rapamycin inhibitor, induced Bim and p27 expressions.	U 0126	32-37	mechanistic target of rapamycin kinase	Homo sapiens	113-142	
26620226-8	2016	The inhibitors LY294002 (PI3K-AKT inhibitor), U0126 (inhibitor of ERK1/2) and rapamycin (mTOR inhibitor) also blocked the ability of EGF to increase HIF-1alpha protein and to phosphorylate AKT, ERK1/2 and mTOR proteins.	U 0126	46-51	mechanistic target of rapamycin kinase	Homo sapiens	205-209